Another JNK inhibitor, CC-930, exhibits specificity for JNK1 and is currently in phase II clinical trials for idiopathic pulmonary fibrosis, but it presents some cardiac adverse effects (Krenitsky et al., 2012). The gene discussed is MAPK8; the disease is pulmonary fibrosis.